Evidence map›Paper›PMID 39806206›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Predictive and prognostic value of

Hyehyun Jeong, Jeongryul Ryu, Jae Ho Jeong, Sangwon Han, Jaewon Hyung, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Byung-Kwan Jeong, Hee Jin Lee and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CouldDiagnostics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hyehyun JeongDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jeongryul RyuDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.
Jae Ho JeongDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. jaeho.jeong@amc.seoul.kr.
Sangwon HanDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea. hswon87@naver.com.ORCID 0000-0001-8095-0396
Jaewon HyungDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jin-Hee AhnDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kyung Hae JungDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Sung-Bae KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Byung-Kwan JeongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hee Jin LeeDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Gyungyub GongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Dae Hyuk MoonDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Funding

Korea Health Industry Development Institute HR18C0016
6 · The paper itself

Abstract

purposeEstrogen receptor (ER) expression and heterogeneity affect endocrine therapy efficacy.

methodsPatients were identified from a prospective cohort for post-marketing surveillance of

resultsA total of 127 women were included. The endocrine therapy used was aromatase inhibitors in 96 patients (76%) and fulvestrant in 31 patients (24%). There were 25 (20%) and 102 (80%) patients in the "with FES-negative" (3 completely negative, 22 mixed) and "FES-positive" groups, respectively.

conclusionER expression determined by

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6EstradiolPositron Emission Tomography Computed TomographyProtein Kinase InhibitorsAdultAgedFemaleHumansMiddle AgedNeoplasm MetastasisPrognosisRetrospective Studies16-fluoroestradiolCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6EstradiolProtein Kinase Inhibitors18F-FES PETBreast cancerCDK4/6 inhibitorsEndocrine therapyPredictive biomarker

Identifiers

PMID39806206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.